Literature DB >> 22496461

SAP155-mediated splicing of FUSE-binding protein-interacting repressor serves as a molecular switch for c-myc gene expression.

Kazuyuki Matsushita1, Toshiko Kajiwara, Mai Tamura, Mamoru Satoh, Nobuko Tanaka, Takeshi Tomonaga, Hisahiro Matsubara, Hideaki Shimada, Rei Yoshimoto, Akihiro Ito, Shuji Kubo, Tohru Natsume, David Levens, Minoru Yoshida, Fumio Nomura.   

Abstract

The Far UpStream Element (FUSE)-binding protein-interacting repressor (FIR), a c-myc transcriptional suppressor, is alternatively spliced removing the transcriptional repression domain within exon 2 (FIRΔexon2) in colorectal cancers. SAP155 is a subunit of the essential splicing factor 3b (SF3b) subcomplex in the spliceosome. This study aims to study the significance of the FIR-SAP155 interaction for the coordination of c-myc transcription, pre-mRNA splicing, and c-Myc protein modification, as well as to interrogate FIRΔexon2 for other functions relating to altered FIR pre-mRNA splicing. Knockdown of SAP155 or FIR was used to investigate their reciprocal influence on each other and on c-myc transcription, pre-mRNA splicing, and protein expression. Pull down from HeLa cell nuclear extracts revealed the association of FIR, FIRΔexon2, and SF3b subunits. FIR and FIRΔexon2 were coimmunoprecipitated with SAP155. FIR and FIRΔexon2 adenovirus vector (Ad-FIR and Ad-FIRΔexon2, respectively) were prepared to test for their influence on c-myc expression. FIR, SAP155, SAP130, and c-myc were coordinately upregulated in human colorectal cancer. These results reveal that SAP155 and FIR/FIRΔexon2 form a complex and are mutually upregulating. Ad-FIRΔexon2 antagonized Ad-FIR transcriptional repression of c-myc in HeLa cells. Because FIRΔexon2 still carries RRM1 and RRM2 and binding activity to FUSE, it is able to displace repression competent FIR from FUSE in electrophoretic mobility shift assays, thus thwarting FIR-mediated transcriptional repression by FUSE. Thus aberrant FIRΔexon2 production in turn sustained c-Myc expression. In conclusion, altered FIR and c-myc pre-mRNA splicing, in addition to c-Myc expression by augmented FIR/FIRΔexon2-SAP155 complex, potentially contribute to colorectal cancer development. 2012 AACR

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22496461      PMCID: PMC7469880          DOI: 10.1158/1541-7786.MCR-11-0462

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  39 in total

1.  A direct nanoflow liquid chromatography-tandem mass spectrometry system for interaction proteomics.

Authors:  Tohru Natsume; Yoshio Yamauchi; Hiroshi Nakayama; Takashi Shinkawa; Mitsuaki Yanagida; Nobuhiro Takahashi; Toshiaki Isobe
Journal:  Anal Chem       Date:  2002-09-15       Impact factor: 6.986

2.  Spliceostatin A blocks angiogenesis by inhibiting global gene expression including VEGF.

Authors:  Ryohei Furumai; Kazuyo Uchida; Yusuke Komi; Misao Yoneyama; Ken Ishigami; Hidenori Watanabe; Soichi Kojima; Minoru Yoshida
Journal:  Cancer Sci       Date:  2010-11       Impact factor: 6.716

3.  Defective interplay of activators and repressors with TFIH in xeroderma pigmentosum.

Authors:  J Liu; S Akoulitchev; A Weber; H Ge; S Chuikov; D Libutti; X W Wang; J W Conaway; C C Harris; R C Conaway; D Reinberg; D Levens
Journal:  Cell       Date:  2001-02-09       Impact factor: 41.582

4.  Centromere protein H is up-regulated in primary human colorectal cancer and its overexpression induces aneuploidy.

Authors:  Takeshi Tomonaga; Kazuyuki Matsushita; Masumi Ishibashi; Masahiko Nezu; Hideaki Shimada; Takenori Ochiai; Kinya Yoda; Fumio Nomura
Journal:  Cancer Res       Date:  2005-06-01       Impact factor: 12.701

5.  Frequent pathway mutations of splicing machinery in myelodysplasia.

Authors:  Kenichi Yoshida; Masashi Sanada; Yuichi Shiraishi; Daniel Nowak; Yasunobu Nagata; Ryo Yamamoto; Yusuke Sato; Aiko Sato-Otsubo; Ayana Kon; Masao Nagasaki; George Chalkidis; Yutaka Suzuki; Masashi Shiosaka; Ryoichiro Kawahata; Tomoyuki Yamaguchi; Makoto Otsu; Naoshi Obara; Mamiko Sakata-Yanagimoto; Ken Ishiyama; Hiraku Mori; Florian Nolte; Wolf-Karsten Hofmann; Shuichi Miyawaki; Sumio Sugano; Claudia Haferlach; H Phillip Koeffler; Lee-Yung Shih; Torsten Haferlach; Shigeru Chiba; Hiromitsu Nakauchi; Satoru Miyano; Seishi Ogawa
Journal:  Nature       Date:  2011-09-11       Impact factor: 49.962

6.  Analysis of M phase-specific phosphorylation of DNA topoisomerase II.

Authors:  K Kimura; N Nozaki; T Enomoto; M Tanaka; A Kikuchi
Journal:  J Biol Chem       Date:  1996-08-30       Impact factor: 5.157

7.  A novel protein-conjugating system for Ufm1, a ubiquitin-fold modifier.

Authors:  Masaaki Komatsu; Tomoki Chiba; Kanako Tatsumi; Shun-ichiro Iemura; Isei Tanida; Noriko Okazaki; Takashi Ueno; Eiki Kominami; Tohru Natsume; Keiji Tanaka
Journal:  EMBO J       Date:  2004-04-08       Impact factor: 11.598

8.  A sequence-specific, single-strand binding protein activates the far upstream element of c-myc and defines a new DNA-binding motif.

Authors:  R Duncan; L Bazar; G Michelotti; T Tomonaga; H Krutzsch; M Avigan; D Levens
Journal:  Genes Dev       Date:  1994-02-15       Impact factor: 11.361

9.  Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts.

Authors:  E Papaemmanuil; M Cazzola; J Boultwood; L Malcovati; P Vyas; D Bowen; A Pellagatti; J S Wainscoat; E Hellstrom-Lindberg; C Gambacorti-Passerini; A L Godfrey; I Rapado; A Cvejic; R Rance; C McGee; P Ellis; L J Mudie; P J Stephens; S McLaren; C E Massie; P S Tarpey; I Varela; S Nik-Zainal; H R Davies; A Shlien; D Jones; K Raine; J Hinton; A P Butler; J W Teague; E J Baxter; J Score; A Galli; M G Della Porta; E Travaglino; M Groves; S Tauro; N C Munshi; K C Anderson; A El-Naggar; A Fischer; V Mustonen; A J Warren; N C P Cross; A R Green; P A Futreal; M R Stratton; P J Campbell
Journal:  N Engl J Med       Date:  2011-09-26       Impact factor: 91.245

10.  c-myc suppressor FBP-interacting repressor for cancer diagnosis and therapy.

Authors:  Kazuyuki Matsushita; Takeshi Tomonaga; Toshiko Kajiwara; Hideaki Shimada; Sakae Itoga; Takaki Hiwasa; Shuji Kubo; Takenori Ochiai; Hisahiro Matsubara; Fumio Nomura
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01
View more
  14 in total

1.  Non-transmissible Sendai virus vector encoding c-myc suppressor FBP-interacting repressor for cancer therapy.

Authors:  Kazuyuki Matsushita; Hideaki Shimada; Yasuji Ueda; Makoto Inoue; Mamoru Hasegawa; Takeshi Tomonaga; Hisahiro Matsubara; Fumio Nomura
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

Review 2.  Alternative splicing of DNA damage response genes and gastrointestinal cancers.

Authors:  Bahityar Rahmutulla; Kazuyuki Matsushita; Fumio Nomura
Journal:  World J Gastroenterol       Date:  2014-12-14       Impact factor: 5.742

3.  Sendai virus-mediated gene transfer of the c-myc suppressor far-upstream element-binding protein-interacting repressor suppresses head and neck cancer.

Authors:  N Tanaka; K Araki; D Mizokami; Y Miyagawa; T Yamashita; M Tomifuji; Y Ueda; M Inoue; K Matsushita; F Nomura; H Shimada; A Shiotani
Journal:  Gene Ther       Date:  2015-01-15       Impact factor: 5.250

4.  Interactions between SAP155 and FUSE-binding protein-interacting repressor bridges c-Myc and P27Kip1 expression.

Authors:  Kazuyuki Matsushita; Mai Tamura; Nobuko Tanaka; Takeshi Tomonaga; Hisahiro Matsubara; Hideaki Shimada; David Levens; Liusheng He; Juhong Liu; Minoru Yoshida; Fumio Nomura
Journal:  Mol Cancer Res       Date:  2013-04-17       Impact factor: 5.852

5.  Adenovirus-mediated FIR demonstrated TP53-independent cell-killing effect and enhanced antitumor activity of carbon-ion beams.

Authors:  M Kano; K Matsushita; B Rahmutulla; S Yamada; H Shimada; S Kubo; T Hiwasa; H Matsubara; F Nomura
Journal:  Gene Ther       Date:  2015-08-04       Impact factor: 5.250

6.  Haploinsufficiency of the c-myc transcriptional repressor FIR, as a dominant negative-alternative splicing model, promoted p53-dependent T-cell acute lymphoblastic leukemia progression by activating Notch1.

Authors:  Kazuyuki Matsushita; Kouichi Kitamura; Bahityar Rahmutulla; Nobuko Tanaka; Takayuki Ishige; Mamoru Satoh; Tyuji Hoshino; Satoru Miyagi; Takeshi Mori; Sakae Itoga; Hideaki Shimada; Takeshi Tomonaga; Minoru Kito; Yaeko Nakajima-Takagi; Shuji Kubo; Chiaki Nakaseko; Masahiko Hatano; Takashi Miki; Masafumi Matsuo; Masaki Fukuyo; Atsushi Kaneda; Atsushi Iwama; Fumio Nomura
Journal:  Oncotarget       Date:  2015-03-10

7.  Gene therapy of c-myc suppressor FUSE-binding protein-interacting repressor by Sendai virus delivery prevents tracheal stenosis.

Authors:  Daisuke Mizokami; Koji Araki; Nobuaki Tanaka; Hiroshi Suzuki; Masayuki Tomifuji; Taku Yamashita; Yasuji Ueda; Hideaki Shimada; Kazuyuki Matsushita; Akihiro Shiotani
Journal:  PLoS One       Date:  2015-01-08       Impact factor: 3.240

Review 8.  The RNA Splicing Response to DNA Damage.

Authors:  Lulzim Shkreta; Benoit Chabot
Journal:  Biomolecules       Date:  2015-10-29

9.  Alternative splicing of FBP-interacting repressor coordinates c-Myc, P27Kip1/cyclinE and Ku86/XRCC5 expression as a molecular sensor for bleomycin-induced DNA damage pathway.

Authors:  Bahityar Rahmutulla; Kazuyuki Matsushita; Mamoru Satoh; Masanori Seimiya; Sachio Tsuchida; Shuji Kubo; Hideaki Shimada; Masayuki Ohtsuka; Masaru Miyazaki; Fumio Nomura
Journal:  Oncotarget       Date:  2014-05-15

10.  FIR haplodeficiency promotes splicing to pyruvate kinase M2 in mice thymic lymphoma tissues revealed by six-plex tandem mass tag quantitative proteomic analysis.

Authors:  Asako Kimura; Kouichi Kitamura; Guzhanuer Ailiken; Mamoru Satoh; Toshinari Minamoto; Nobuko Tanaka; Fumio Nomura; Kazuyuki Matsushita
Journal:  Oncotarget       Date:  2017-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.